| Market Capitalization (Millions $) |
136,781 |
| Shares
Outstanding (Millions) |
2,047 |
| Employees |
32,500 |
| Revenues (TTM) (Millions $) |
48,482 |
| Net Income (TTM) (Millions $) |
7,271 |
| Cash Flow (TTM) (Millions $) |
-1,292 |
| Capital Exp. (TTM) (Millions $) |
1,398 |
Business Description
Bristol-Myers Squibb Company Overview
Incorporation and History:
Bristol-Myers Squibb Company (BMS) was incorporated in August 1933 in Delaware as Bristol-Myers Company. Its origins trace back to 1887 with a New York-based business. In 1989, the company underwent a significant transformation, merging with Squibb Corporation and adopting the name Bristol-Myers Squibb Company.
Business Segments:
Bristol-Myers Squibb is a global biopharmaceutical company focusing on the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and healthcare products. The company is organized into four reportable segments:
1. Pharmaceuticals: This segment encompasses the global pharmaceutical business, including exclusive consumer medicines outside Japan. BMSs portfolio includes a range of therapeutic areas such as cardiovascular disease, immunology, and virology.
2. Oncology Therapeutics Network (OTN): The OTN segment provides oncology products, supportive care products, and related supplies to U.S. office-based oncologists, focusing on providing integrated solutions for cancer treatment.
3. Nutritionals: This segment includes Mead Johnson Nutritionals, a leading brand in infant formula and nutritional products for infants and children, emphasizing nutritional science and product innovation.
4. Other Healthcare: This diverse segment includes businesses such as ConvaTec (which focuses on advanced wound care, continence, and urology), Medical Imaging, and consumer medicines marketed in North America and Japan.
Marketing and Sales Strategies:
Bristol-Myers Squibb employs a robust marketing strategy that includes promoting its products through medical journals and direct communication with healthcare providers, including doctors, nurse practitioners, and hospitals. In addition, the company engages in direct-to-consumer advertising across various media platforms in the United States.
The company operates several pharmaceutical sales organizations tailored to specific therapeutic areas and physician specialties. These targeted sales strategies are particularly effective when launching new products, enabling focused marketing efforts that tap into specialized care environments.
Distribution Channels:
Bristol-Myers Squibbs pharmaceutical products are primarily sold to wholesalers, though direct sales are made to various healthcare entities, including retailers, hospitals, clinics, government agencies, and pharmacies. Major wholesalers in the U.S. market include McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation.
Competitive Landscape:
Bristol-Myers Squibb operates in a highly competitive landscape characterized by broad market participation from both large research-based drug companies and smaller firms focused on niche therapeutic areas. The main competitive factors influencing the pharmaceutical segment include:
- Product Efficacy and Safety: Ensuring that drugs provide favorable outcomes and are well-tolerated by patients.
- Cost-Effectiveness: Demonstrating value through pricing and economic benefits of therapy.
- Marketing and Labeling: Effectiveness in communication to both healthcare providers and patients, including drug labeling and educational efforts.
- Innovation in Research and Development: Ongoing investment in research to bring new therapeutic options to market, particularly in response to emerging health needs and diseases.
The competitiveness is further intensified by the quick adoption and potential market penetration of generic drugs, which can significantly impact the sales of branded pharmaceuticals. Consequently, BMS remains diligent in monitoring clinical studies and market dynamics that could affect its product performance.
Recent Developments and Focus Areas:
Bristol-Myers Squibb continuously emphasizes research and innovation, focusing on the development of breakthrough therapies in oncology, immunology, and cardiovascular disease. The company has made strides in precision medicine and targeted therapies, enhancing treatment options for patients with various conditions. Additionally, Bristol-Myers Squibb is increasingly investing in digital health solutions and collaborative partnerships as part of its strategic approach to healthcare delivery and education.
Overall, Bristol-Myers Squibb remains committed to advancing medical science and improving patient outcomes through its comprehensive portfolio and strategic initiatives in drug discovery and development.
Company Address: Route 206 & Province Line Road Zagreb 8543 City of Zagreb
Company Phone Number: 252-4621 Stock Exchange / Ticker: NYSE BMY
|
0.38% 
97.21 %